Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea
© 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
Ethical approval for the study was obtained from the ethics committee of Chungnam National University Hospital (CNUH-IRB 2021-12-001) (Daejeon, Republic of Korea). An exemption from informed consent was also approved.
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
Conflicts of Interest
The authors declare that they have no potential conflicts of interest.
Author Contributions
Conceptualization: MKY, KSS. Data curation: DHK, IOS. Funding acquisition: KSS. Investigation: DHK, IOS. Methodology: MKY, GEB, KSS. Project administration: KSS. Resources: KSS, IOS. Supervision: KSS. Validation: MKY, GEB. Visualization: DHK, KSS. Writing—original draft: MKY, KSS. Writing—review & editing: MKY, KSS. Approval of final manuscript: all authors.
Funding Statement
This work was supported by research fund of Chungnam National University.
Clinicopathologic findings | GEA (n = 10) | UEA (n = 12) |
---|---|---|
Age (yr) | ||
Mean ± SD | 61.7 ± 11.9 | 45.3 ± 10.9 |
Range | 48–80 | 31–68 |
Type of surgical treatment | ||
Radical hysterectomy | 7 (70.0) | 8 (66.7) |
Total hysterectomy | 0 | 3 (25.0) |
Trachelectomy | 1 (10.0) | 0 |
Conization | 2 (20.0) | 1 (8.3) |
FIGO stage | ||
I | 1 (10.0) | 9 (75.0) |
II | 4 (40.0) | 1 (8.3) |
III | 3 (30.0) | 2 (16.7) |
IV | 2 (20.0) | 0 |
Human papillomavirus status | ||
High-risk HPV | 0 | 12 (100) |
Not detected | 10 (100) | 0 |
p16 expression | ||
Block positive | 1 (10.0) | 12 (100) |
Patchy positive/negative | 9 (90.0) | 0 |
p53 expression | ||
Diffuse strong positive | 5 (50.0) | 0 |
Complete loss (null) | 1 (10.0) | 0 |
Patchy positive | 4 (40.0) | 12 (100) |
Follow-up results | ||
No evidence of disease | 2 (20.0) | 9 (75.0) |
Alive with disease | 3 (30.0) | 0 (0.0) |
Died of disease | 4 (40.0) | 0 (0.0) |
Died of other disease | 0 | 1a (8.3) |
Not available | 1 (10.0) | 2 (16.7) |
Case No. | Age (yr) | Preparation type | Cytologic diagnosis | Type of surgery | FIGO stage | HPV | p16 | p53 | MUC-6 | Adjuvant treatment | Follow-up (mo) | Outcome | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||
CS | LBP | ||||||||||||
1 | 48 | + | + | AIS | Trachelectomy | IVA | − | − | + | + | CC | 20 | DOD |
2 | 80 | + | + | Adenocarcinoma | RH | IIB | − | − | Wild | −a | RT | 38 | DOD |
3 | 52 | + | + | AGC | RH | IIIC1 | − | − | Wild | + | CCRT | 48 | AWD |
4 | 58 | + | + | Adenocarcinoma | RH | IVA | −b | − | + | + | CC | 23 | DOD |
5 | 54 | + | + | Adenocarcinoma | RH | IIA1 | − | + | + | + | NA | FU loss | NA |
6 | 54 | NA | NA | NA | Conization | IIIC1 | − | − | Wild | + | CCRT | 17 | DOD |
7 | 78 | NA | + | Adenocarcinoma | Conization | IIA2 | − | − | + | −a | RT | 21 | NED |
8 | 63 | NA | + | AGC | RH | IB1 | − | − | Null | + | CCRT | 21 | NED |
9 | 76 | NA | + | AGC | RH | IIB | − | − | + | + | RT | 10 | AWD |
10 | 54 | NA | NA | NA | RH | IIIC1 | − | − | Wild | + | CCRT | 10 | AWD |
CS, conventional smear; LBP, liquid-based preparation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; AIS, adenocarcinoma in situ; CC, combined chemotherapy; DOD, died of disease; RH, radical hysterectomy; RT, radiotherapy; AGC, atypical glandular cells, favor neoplastic; CCRT, combined chemotherapy and radiotherapy; AWD, alive with disease; NA, not available; FU, follow-up; NED, no evidence of disease.
aPale pinkish-red cytoplasmic neutral mucin on Alcian blue/PAS special staining;
bHigh risk HPV DNA in situ hybridization; +, p16, block-type positivity; +, p53, overexpression.
Kawakami et al. [12] | Lu et al. [11] | Schwock et al. [13] | Ryu et al. [15] | This study | Total, n (%) | |
---|---|---|---|---|---|---|
No. of cases | 14 | 11 | 15 | 8 | 8 | 56 (100) |
Preparation type | CS | LBC | CS and LBC | CS and LBC | CS and/or LBC | CS and/or LBC |
TBS classification | ||||||
Unsatisfactory | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
NILM | 0 | 5 | 5 | 0 | 0 | 10 (17.9) |
AGC | 3 | 4 | 2 | 4 | 3 | 16 (28.6) |
AIS | 0 | 0 | 1 | 1 | 1 | 3 (5.4) |
HSIL | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
Adenocarcinoma | 11 | 0 | 7 | 3 | 4 | 25 (44.6) |
GEA, gastric-type endocervical adenocarcinoma; CS, conventional smear; LBC, liquid-based cytology; TBS, The Bethesda System; NILM, negative for intraepithelial lesion or malignancy; AGC, atypical glandular cells, not otherwise specified and favor adenocarcinoma; AIS, adenocarcinoma in situ; HSIL, high-grade squamous intraepithelial lesion.
Clinicopathologic findings | GEA (n = 10) | UEA (n = 12) |
---|---|---|
Age (yr) | ||
Mean ± SD | 61.7 ± 11.9 | 45.3 ± 10.9 |
Range | 48–80 | 31–68 |
Type of surgical treatment | ||
Radical hysterectomy | 7 (70.0) | 8 (66.7) |
Total hysterectomy | 0 | 3 (25.0) |
Trachelectomy | 1 (10.0) | 0 |
Conization | 2 (20.0) | 1 (8.3) |
FIGO stage | ||
I | 1 (10.0) | 9 (75.0) |
II | 4 (40.0) | 1 (8.3) |
III | 3 (30.0) | 2 (16.7) |
IV | 2 (20.0) | 0 |
Human papillomavirus status | ||
High-risk HPV | 0 | 12 (100) |
Not detected | 10 (100) | 0 |
p16 expression | ||
Block positive | 1 (10.0) | 12 (100) |
Patchy positive/negative | 9 (90.0) | 0 |
p53 expression | ||
Diffuse strong positive | 5 (50.0) | 0 |
Complete loss (null) | 1 (10.0) | 0 |
Patchy positive | 4 (40.0) | 12 (100) |
Follow-up results | ||
No evidence of disease | 2 (20.0) | 9 (75.0) |
Alive with disease | 3 (30.0) | 0 (0.0) |
Died of disease | 4 (40.0) | 0 (0.0) |
Died of other disease | 0 | 1 |
Not available | 1 (10.0) | 2 (16.7) |
Case No. | Age (yr) | Preparation type | Cytologic diagnosis | Type of surgery | FIGO stage | HPV | p16 | p53 | MUC-6 | Adjuvant treatment | Follow-up (mo) | Outcome | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
CS | LBP | ||||||||||||
1 | 48 | + | + | AIS | Trachelectomy | IVA | − | − | + | + | CC | 20 | DOD |
2 | 80 | + | + | Adenocarcinoma | RH | IIB | − | − | Wild | − |
RT | 38 | DOD |
3 | 52 | + | + | AGC | RH | IIIC1 | − | − | Wild | + | CCRT | 48 | AWD |
4 | 58 | + | + | Adenocarcinoma | RH | IVA | − |
− | + | + | CC | 23 | DOD |
5 | 54 | + | + | Adenocarcinoma | RH | IIA1 | − | + | + | + | NA | FU loss | NA |
6 | 54 | NA | NA | NA | Conization | IIIC1 | − | − | Wild | + | CCRT | 17 | DOD |
7 | 78 | NA | + | Adenocarcinoma | Conization | IIA2 | − | − | + | − |
RT | 21 | NED |
8 | 63 | NA | + | AGC | RH | IB1 | − | − | Null | + | CCRT | 21 | NED |
9 | 76 | NA | + | AGC | RH | IIB | − | − | + | + | RT | 10 | AWD |
10 | 54 | NA | NA | NA | RH | IIIC1 | − | − | Wild | + | CCRT | 10 | AWD |
Cytologic finding | GEA (n=8) | UEA (n=12) | p-value |
---|---|---|---|
Mucinous background | .058 | ||
Absent | 2 (25.0) | 2 (16.7) | |
Focal | 2 (25.0) | 9 (75.0) | |
Extensive | 4 (50.0) | 1 (8.3) | |
Architecture | |||
Monolayered honeycomb-like sheet | .002 | ||
Absent | 0 | 6 (50.0) | |
Focal | 1 (12.5) | 5 (41.7) | |
Extensive | 7 (87.5) | 1 (8.3) | |
3-dimensional clusters | .010 | ||
Absent | 0 | 0 | |
Focal | 5 (62.5) | 1 (8.3) | |
Extensive | 3 (37.5) | 11 (91.7) | |
Feathering | .189 | ||
Absent | 3 (37.5) | 3 (25.0) | |
Focal | 5 (62.5) | 5 (41.7) | |
Extensive | 0 | 4 (33.3) | |
Nuclei | |||
Vesicular nuclei | .057 | ||
Absent | 0 (0.0) | 1 (8.3) | |
Focal | 0 (0.0) | 5 (41.7) | |
Extensive | 8 (100.0) | 6 (50.0) | |
Hyperchromasia | .082 | ||
Absent | 2 (25.0) | 0 | |
Focal | 6 (75.0) | 9 (75.0) | |
Extensive | 0 (0.0) | 3 (25.0) | |
Nuclear groove | .230 | ||
Absent | 0 (0.0) | 3 (25.0) | |
Focal | 6 (75.0) | 8 (66.7) | |
Extensive | 2 (25.0) | 1 (8.3) | |
Nucleoli | .146 | ||
Absent | 0 (0.0) | 3 (25.0) | |
Focal | 3 (37.5) | 6 (50.0) | |
Extensive | 5 (62.5) | 3 (25.0) | |
Intranuclear pseudoinclusion | .761 | ||
Absent | 7 (87.5) | 11 (91.7) | |
Focal | 1 (12.5) | 1 (8.3) | |
Extensive | 0 | 0 | |
Cytoplasm | |||
Vacuolar/granular | .001 | ||
Absent | 0 | 2 (16.7) | |
Focal | 0 | 8 (66.7) | |
Extensive | 8 (100) | 2 (16.7) | |
Golden-brown mucin | .089 | ||
Absent | 3 (37.5) | 10 (83.3) | |
Focal | 4 (50.0) | 2 (16.7) | |
Extensive | 1 (12.5) | 0 | |
Neutrophils | .461 | ||
Absent | 0 | 1 (8.3) | |
Focal | 2 (25.0) | 5 (41.7) | |
Extensive | 6 (75.0) | 6 (50.0) |
Kawakami et al. [ |
Lu et al. [ |
Schwock et al. [ |
Ryu et al. [ |
This study | Total, n (%) | |
---|---|---|---|---|---|---|
No. of cases | 14 | 11 | 15 | 8 | 8 | 56 (100) |
Preparation type | CS | LBC | CS and LBC | CS and LBC | CS and/or LBC | CS and/or LBC |
TBS classification | ||||||
Unsatisfactory | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
NILM | 0 | 5 | 5 | 0 | 0 | 10 (17.9) |
AGC | 3 | 4 | 2 | 4 | 3 | 16 (28.6) |
AIS | 0 | 0 | 1 | 1 | 1 | 3 (5.4) |
HSIL | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
Adenocarcinoma | 11 | 0 | 7 | 3 | 4 | 25 (44.6) |
Values are presented as number (%) unless otherwise indicated. GEA, gastric-type endocervical adenocarcinoma; UEA, usual-type endocervical adenocarcinoma; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus. Died of stomach cancer.
CS, conventional smear; LBP, liquid-based preparation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; AIS, adenocarcinoma in situ; CC, combined chemotherapy; DOD, died of disease; RH, radical hysterectomy; RT, radiotherapy; AGC, atypical glandular cells, favor neoplastic; CCRT, combined chemotherapy and radiotherapy; AWD, alive with disease; NA, not available; FU, follow-up; NED, no evidence of disease. Pale pinkish-red cytoplasmic neutral mucin on Alcian blue/PAS special staining; High risk HPV DNA in situ hybridization; +, p16, block-type positivity; +, p53, overexpression.
GEA, gastric-type endocervical adenocarcinoma; CS, conventional smear; LBC, liquid-based cytology; TBS, The Bethesda System; NILM, negative for intraepithelial lesion or malignancy; AGC, atypical glandular cells, not otherwise specified and favor adenocarcinoma; AIS, adenocarcinoma in situ; HSIL, high-grade squamous intraepithelial lesion.